JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GREEN, H. D.
Right arrow Articles by BOYER, N. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by GREEN, H. D.
Right arrow Articles by BOYER, N. H.
Journal of Pharmacology And Experimental Therapeutics, Vol. 76, Issue 4, 378-391, 1942
Copyright © 1942 by American Society for Pharmacology and Experimental Therapeutics

EFFECTS OF EPINEPHRINE AND PITRESSIN ON THE CORONARY ARTERY INFLOW IN ANESTHETIZED DOGS

HAROLD D. GREEN 1, RENÉ WÉGRIA 1, and NORMAN H. BOYER 1

1 From the Department of Physiology, School of Medicine, Western Reserve University, Cleveland, Ohio

Pitressin is an intense coronary constrictor capable, upon intracoronary injection, of causing sufficient constriction and reduction of coronary flow to depress the contractile effort of the myocardium.

Epinephrine is not a coronary constrictor in the dog. On the other hand, while the coronary flow increases after injection of the drug, this increase with the pure alkaloid is not much greater than would be anticipated from the rise of aortic pressure and follows by an interval of many seconds the appearance of myocardial stimulation induced by the drug. It is concluded therefore that epineprhine has only a weak coronary dilating effect per se, and that the apparently prominent coronary dilator action observed, particularly with the 1:1000 solution, is due in large part to a marked increase of myocardial metabolic activity, out of proportion to the increased cardiac work, to a coronary dilator effect of the preservative, and to a relative increase in the total diastolic time per minute due to shortening of the S/C ratio.

Angina following epinephrine injection is probably due to failure of the drug to induce directly sufficient coronary dilation and increased blood flow, to supply the augmented myocardial metabolism, resulting in a relative myocardial ischemia.

Submitted on August 31, 1942




This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
S.D. Moulopoulos, L.P. Anthopoulos, S.F. Stamatelopoulos, and D.A. Sideris
Determinants of Coronary Flow Pattern
Angiology, January 1, 1973; 24(1): 29 - 44.
[PDF]

Home page
 ANGIOLOGYHome page
G. G. Gensini, S. Di Giorgi, S. Murad-Netto, A. Black, and A. E. Kelly
Arteriographic Demonstration of Coronary Artery Spasm and Its Release After the Use of a Vasodilator in a Case of Angina Pectoris and in the Experimental Animal
Angiology, December 1, 1962; 13(12): 550 - 553.
[PDF]

Home page
 ANGIOLOGYHome page
W.W. Oppelt and H.E. Ederstrom
The Comparative Sensitivity of Isolated Coronary and Systemic Vessels To Vasomotor Agents
Angiology, June 1, 1959; 10(3): 153 - 157.
[PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1942 by the American Society for Pharmacology and Experimental Therapeutics.